Work

Faculty Opinions recommendation of Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.

Year: 2023

Type: peer-review

Source: Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

DOI: 10.3410/f.742667047.793600414

Author: Erminia Massarelli

Institutions: City Of Hope National Medical Center, City of Hope

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4385954493

Cites:

Cited by:

Related to: 10